|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
ES2113879T3
(es)
|
1990-01-24 |
1998-05-16 |
Douglas I Buckley |
Analogos de glp-1 utiles para el tratamiento de diabetes.
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DE122009000079I2
(de)
|
1996-08-30 |
2011-06-16 |
Novo Nordisk As Novo Alle |
Glp-1 derivate
|
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
EP2319854B1
(en)
|
1997-01-08 |
2016-11-30 |
Sigma-Aldrich Co. LLC |
Bioconjugation Of Macromolecules
|
|
JP2002508162A
(ja)
|
1998-02-27 |
2002-03-19 |
ノボ ノルディスク アクティーゼルスカブ |
Ｎ末端を短縮したｇｌｐ−１誘導体
|
|
EP1060191B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
DE69916811T2
(de)
|
1998-02-27 |
2005-04-14 |
Novo Nordisk A/S |
Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
|
|
AU5027299A
(en)
|
1998-07-31 |
2000-02-28 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
|
SI1724284T1
(sl)
*
|
2000-12-07 |
2009-12-31 |
Lilly Co Eli |
Glp-1 fuzijski proteini
|
|
ES2464532T3
(es)
|
2001-04-19 |
2014-06-03 |
The Scripps Research Institute |
Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
JP5275566B2
(ja)
|
2003-06-18 |
2013-08-28 |
ザ スクリプス リサーチ インスティチュート |
反応性非天然アミノ酸遺伝コード付加
|
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
CN100444898C
(zh)
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
JP2007537141A
(ja)
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
新規なｇｌｐ−１化合物
|
|
CN101665538A
(zh)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
|
EP1771205B1
(en)
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性ｇｌｐ−１化合物
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
ES2484796T3
(es)
|
2005-03-18 |
2014-08-12 |
Novo Nordisk A/S |
Compuestos de GLP-1 extendidos
|
|
ATE507235T1
(de)
|
2006-02-08 |
2011-05-15 |
Lonza Ag |
Synthese von glucagon-ähnlichen peptiden
|
|
CA2644712C
(en)
|
2006-03-06 |
2016-09-13 |
Amunix, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2653748A1
(en)
|
2006-05-02 |
2007-11-15 |
Allozyne, Inc. |
Non-natural amino acid substituted polypeptides
|
|
US8563521B2
(en)
|
2007-06-21 |
2013-10-22 |
Technische Universitat Munchen |
Biological active proteins having increased in vivo and/or in vitro stability
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
CN102149411A
(zh)
|
2008-09-12 |
2011-08-10 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
US20120329711A1
(en)
|
2009-12-16 |
2012-12-27 |
Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
|
EP4450523A3
(en)
|
2010-04-02 |
2025-03-12 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
TW201203798A
(en)
|
2010-07-01 |
2012-01-16 |
Tricore Corp |
Tray sealant filling fixture for spindle motor and the sealant filling method
|
|
JP6231386B2
(ja)
|
2010-11-09 |
2017-11-15 |
ノヴォ ノルディスク アー／エス |
リンカーを有する二重アシル化されたｇｌｐ−１誘導体
|
|
AU2012241894B2
(en)
*
|
2011-04-12 |
2015-12-03 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
|
JP6126097B2
(ja)
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体
|
|
ES2687651T3
(es)
|
2011-09-12 |
2018-10-26 |
Amunix Operating Inc. |
Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
JP6254146B2
(ja)
|
2012-03-27 |
2017-12-27 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
代謝障害を治療するための組成物および方法
|
|
EP2846823B1
(en)
|
2012-05-08 |
2019-12-04 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
CN104411322B
(zh)
|
2012-05-08 |
2017-05-24 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
|
CN107320719A
(zh)
|
2012-06-05 |
2017-11-07 |
阿穆尼克斯运营公司 |
Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途
|
|
ES2770501T3
(es)
|
2012-07-11 |
2020-07-01 |
Bioverativ Therapeutics Inc |
Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
|
|
WO2014060472A1
(en)
|
2012-10-17 |
2014-04-24 |
Novo Nordisk A/S |
Fatty acid acylated amino acids for oral peptide delivery
|
|
WO2014164568A1
(en)
|
2013-03-11 |
2014-10-09 |
Amunix Operating Inc. |
Treatment of pediatric growth hormone deficiency with human growth hormone analogues
|
|
AU2014283221A1
(en)
|
2013-06-20 |
2015-12-03 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
JP6139712B2
(ja)
|
2013-07-04 |
2017-05-31 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１様ペプチドの誘導体及びその使用
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
|
CN104987383A
(zh)
*
|
2014-07-08 |
2015-10-21 |
四川百利药业有限责任公司 |
一种glp-1衍生物
|
|
WO2016077505A2
(en)
|
2014-11-11 |
2016-05-19 |
Amunix Operating Inc. |
Targeted xten conjugate compositions and methods of making same
|
|
JP6730278B2
(ja)
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
EP3233898A1
(en)
|
2014-12-17 |
2017-10-25 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
|
EP3303380B1
(en)
|
2015-06-02 |
2020-01-15 |
Novo Nordisk A/S |
Insulins with polar recombinant extensions
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
JP6712323B2
(ja)
|
2015-12-31 |
2020-06-17 |
ハンミ ファーマシューティカル カンパニー リミテッド |
グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
|
|
AR107560A1
(es)
|
2016-02-24 |
2018-05-09 |
Lilly Co Eli |
Compuesto que disminuye la glucosa en la sangre
|
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
TWI710377B
(zh)
|
2017-05-23 |
2020-11-21 |
丹麥商諾佛 儂迪克股份有限公司 |
Ｍｉｃ－１化合物及其用途
|
|
CN110945017B
(zh)
|
2017-07-19 |
2024-07-16 |
诺和诺德股份有限公司 |
双功能化合物
|
|
EP3861017A1
(en)
|
2018-10-05 |
2021-08-11 |
Novo Nordisk A/S |
Bifunctional compounds comprising insulin peptides and egf(a) peptides
|
|
AU2020256648B2
(en)
|
2019-04-11 |
2026-01-15 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Multi-receptor agonist and medical use thereof
|
|
SG11202111312UA
(en)
*
|
2019-06-14 |
2021-12-30 |
Zealand Pharma As |
Pharmaceutical parenteral composition of dual glp1/2 agonist
|
|
CN113728013B
(zh)
*
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
CA3193453A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Polypeptide conjugates and methods of uses
|
|
WO2023179796A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
|
|
EP4676535A1
(en)
*
|
2023-03-06 |
2026-01-14 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|